Abstract
Chiral analysis of profens in human plasma is an important area of research due to different pharmaceutical activities of their enantiomers. The solid phase extraction of ibuprofen and flurbiprofen from human plasma was carried out on C18 cartridges by using phosphate buffer (50 mM, pH 6.0) followed by elution with methanol. Chiral-HPLC was performed on AmyCoat RP (150 mm 46 mm, 3 μm particle size) column by using different combinations of wateracetonitrile- trifluoro acetic acid at 1.5 mLmin-1 flow rate. The detection was achieved at 236 and 254 nm for ibuprofen and flurbiprofen, respectively with 27±1°C as working temperature. The chromatographic parameters i.e. retention (k), separation (α) and resolution (Rs) factors ranged from 4.54-14.42, 1.10-1.30 and 1.01-1.49, respectively. The binding differences of enantiomers of ibuprofen and flurbiprofen were 4.4 and 5.2, respectively. These values suggest that S-(+)- enantiomer of flurbiprofen is more active than ibuprofen due to low enantiomeric difference of the later drug. The developed SPE-Chiral HPLC methods were validated, which are selective, efficient and reproducible.
Keywords: Profens, chiral separation, SPE-chiral HPLC, human plasma, plasma protein bindings, enantiomers, non-sterodial anti-inflammatory drugs, prostaglandin, low gastrointestinal complications
Combinatorial Chemistry & High Throughput Screening
Title:Enantiomeric Resolution of Ibuprofen and Flurbiprofen in Human Plasma by SPE-Chiral HPLC Methods
Volume: 15 Issue: 6
Author(s): Imran Ali, Iqbal Hussain, Kishwar Saleem and Hassan Y. Aboul-Enein
Affiliation:
Keywords: Profens, chiral separation, SPE-chiral HPLC, human plasma, plasma protein bindings, enantiomers, non-sterodial anti-inflammatory drugs, prostaglandin, low gastrointestinal complications
Abstract: Chiral analysis of profens in human plasma is an important area of research due to different pharmaceutical activities of their enantiomers. The solid phase extraction of ibuprofen and flurbiprofen from human plasma was carried out on C18 cartridges by using phosphate buffer (50 mM, pH 6.0) followed by elution with methanol. Chiral-HPLC was performed on AmyCoat RP (150 mm 46 mm, 3 μm particle size) column by using different combinations of wateracetonitrile- trifluoro acetic acid at 1.5 mLmin-1 flow rate. The detection was achieved at 236 and 254 nm for ibuprofen and flurbiprofen, respectively with 27±1°C as working temperature. The chromatographic parameters i.e. retention (k), separation (α) and resolution (Rs) factors ranged from 4.54-14.42, 1.10-1.30 and 1.01-1.49, respectively. The binding differences of enantiomers of ibuprofen and flurbiprofen were 4.4 and 5.2, respectively. These values suggest that S-(+)- enantiomer of flurbiprofen is more active than ibuprofen due to low enantiomeric difference of the later drug. The developed SPE-Chiral HPLC methods were validated, which are selective, efficient and reproducible.
Export Options
About this article
Cite this article as:
Ali Imran, Hussain Iqbal, Saleem Kishwar and Y. Aboul-Enein Hassan, Enantiomeric Resolution of Ibuprofen and Flurbiprofen in Human Plasma by SPE-Chiral HPLC Methods, Combinatorial Chemistry & High Throughput Screening 2012; 15 (6) . https://dx.doi.org/10.2174/138620712800563882
DOI https://dx.doi.org/10.2174/138620712800563882 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Biphasic Lipid Vesicles as a Subcutaneous Delivery System for Protein Antigens and CpG Oligonucleotides
Current Drug Delivery Diketo Acids Derivatives as Integrase Inhibitors: The War Against the Acquired Immunodeficiency Syndrome
Recent Patents on Anti-Infective Drug Discovery Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Free Fatty Acid Receptors as New Potential Targets in Colorectal Cancer
Current Drug Targets Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Current Neuropharmacology Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Trafficking Potentials of Unconventional T Cell Subsets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke
Current Drug Targets The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Phenotype Data: A Neglected Resource in Biomedical Research?
Current Bioinformatics The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Current Molecular Medicine (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Immunosuppression in Sepsis
Current Pharmaceutical Design The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Establishing Maternal Tolerance: The Role of Regulatory T Cells (Tregs) in Pregnancy and Pathophysiology of Preeclampsia
Current Women`s Health Reviews NK Cell Receptors and Their Interactions with MHC
Current Pharmaceutical Design A Merger of Rational Drug Design and Combinatorial Chemistry Development and Application of Peptide Secondary Structure Mimetics
Combinatorial Chemistry & High Throughput Screening Synthesis, Crystal Structure, Anti-inflammatory and Anti-hyperglycemic Activities of Novel 3,4-Disubstituted 1,2,4-Triazol-5(4H)-one Derivatives
Medicinal Chemistry